Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shexiang Huayu Xingnao (SX) granules is a Traditional Chinese Medicine (TCM) formulation developed by the Hospital (T.C.M.) Affiliated to Southwest Medical University for the treatment of intracerebral hemorrhage (ICH). It is based on the Fengyaokaixuan therapeutic method. Preclinical studies indicate that SX granules exert neuroprotective effects by reducing brain tissue damage, neuronal apoptosis, and astrocyte activation. Network pharmacology analysis suggests the drug targets multiple signaling pathways, including HRAS, MAPK3 (ERK1), and STAT3, which are involved in inflammation and cell survival. Clinical evaluation focuses on its ability to improve blood-brain barrier permeability and accelerate intracranial hematoma absorption in patients with small-to-medium ICH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shexiang huayu xingnao (Affiliated Hospital of Southwest Medical University).